Table 2 Clinical outcomes and manifestations of the patients included for meta-analysis
No. of study | Author | No. of patients | No. of death | No. of GI symptom | No. of diarrhea | No. of nausea/vomiting | No. of abdominal pain |
|---|---|---|---|---|---|---|---|
1 | Alizadehsani R et al. | 123 | 15 (12.2%) | 11 (8.9%) | NA | NA | NA |
2 | An P et al. | 205 | 6 (2.9%) | 79 (38.5%) | NA | NA | NA |
3 | Atalla E et al. | 111 | 48 (43.2%) | 8 (7.2%) | 8 (7.2%) | 2(1.8%) | NA |
4 | Caillard S et al. | 243 | 43 (17.7%) | 96 (39.5%) | 96 (39.5%) | NA | NA |
5 | Chadalavada P et al. | 84 | 11 (13.1%) | 44 (52.4%) | NA | NA | NA |
6 | Chen R et al. | 1077 | 85 (7.9%) | 359 (33.3%) | NA | NA | NA |
7 | Chen T et al. | 274 | 113 (41.2%) | 77 (28.1%) | 77 (28.1%) | 24(8.8%) | 19(6.9%) |
8 | Comoglu Åž et al. | 1086 | 38 (3.5%) | 78 (7.2%) | 78 (7.2%) | NA | NA |
9 | Crespo M et al. | 414 | 109 (26.3%) | 152 (36.7%) | NA | NA | NA |
10 | Doganci S et al. | 397 | 34 (8.6%) | 292 (73.6%) | NA | NA | NA |
11 | Du H et al. | 182 | 1 (0.5%) | 20 (11.0%) | 9 (4.9%) | 7(3.8%) | 7(3.8%) |
12 | Elimian K et al. | 3215 | 295 (9.2%) | 132 (4.1%) | 132 (4.1%) | 103(3.2%) | 20(0.6%) |
13 | Ferm S et al. | 877 | 208 (23.7%) | 219 (25.0%) | NA | NA | NA |
14 | Gayam V et al. | 408 | 132 (32.4%) | 111 (27.2%) | NA | NA | NA |
15 | Ghoshal U et al. | 252 | 5 (2.0%) | 26 (10.3%) | NA | NA | NA |
16 | Hajifathalian K et al. | 1059 | 147 (13.9%) | 349 (33.0%) | NA | NA | NA |
17 | Huang H et al. | 49 | 9 (18.4%) | 3 (6.1%) | 3 (6.1%) | 1 (2.0%) | NA |
18 | Jiang Y et al. | 281 | 114 (40.6%) | 33 (11.7%) | 33 (11.7%) | 13 (4.6%) | NA |
19 | Jin X et al. | 651 | 1 (0.2%) | 74(11.4%) | NA | NA | NA |
20 | Kang M et al. | 118 | 6 (5.1%) | 54 (45.8%) | 54(45.8%) | NA | NA |
21 | Kim D et al. | 867 | 121 (14.0%) | 181 (20.9%) | 181 (20.9%) | 175 (20.2%) | NA |
22 | Lanthier N et al. | 50 | 26 (52.0%) | 15 (30.0%) | 12 (24.0%) | 3 (6.0%) | 3 (6.0%) |
23 | Laszkowska M et al. | 2804 | 542 (19.3%) | 1084 (38.7%) | NA | NA | NA |
24 | Leal T et al. | 201 | 55 (27.4%) | 60 (29.9%) | NA | NA | NA |
25 | Liang J et al. | 109 | 23 (21.1%) | 26 (23.9%) | 26 (23.9%) | 10 (9.2%) | 5 (4.6%) |
26 | Liu J et al. | 29,393 | 711 (2.4%) | 2289 (7.8%) | NA | NA | NA |
27 | Livanos A et al. | 634 | 151 (23.8%) | 299 (47.2%) | NA | NA | NA |
28 | Luo S et al. | 1411 | 66 (4.7%) | 183 (13.0%) | NA | NA | NA |
29 | Ma X et al. | 467 | 16 (3.4%) | 25 (5.4%) | 25(5.4%) | NA | NA |
30 | Montazeri M et al. | 611 | 104 (17.0%) | 155 (25.4%) | NA | NA | NA |
31 | Moura D et al. | 400 | 89 (22.3%) | 133 (33.3%) | NA | NA | NA |
32 | Nobel Y et al. | 278 | 9 (3.2%) | 97 (34.9%) | 56 (20.1%) | 63 (22.7%) | NA |
33 | Pan L et al. | 204 | 36 (17.6%) | 103 (50.5%) | NA | NA | NA |
34 | Peng X et al. | 49 | 16 (32.7%) | 22 (44.9%) | 11 (22.4%) | 15 (30.6%) | 3(6.1%) |
35 | Ramachandran P et al. | 150 | 58 (38.7%) | 31 (20.7%) | NA | NA | NA |
36 | Redd W et al. | 318 | 32 (10.1%) | 195 (61.3%) | NA | NA | NA |
37 | Renelus B et al. | 734 | 237 (32.3%) | 231 (31.5%) | NA | NA | NA |
38 | Russell B et al. | 156 | 34 (21.8%) | 25 (16.0%) | NA | NA | NA |
39 | Schettino M et al. | 190 | 41 (21.6%) | 138 (72.6%) | NA | NA | NA |
40 | Shang H et al. | 564 | 51 (9.0%) | 157 (27.8%) | 157 (27.8%) | NA | NA |
41 | Soares R et al. | 1152 | 456 (39.6%) | 126 (10.9%) | 126 (10.9%) | NA | NA |
42 | Sulaiman T et al. | 140 | 12 (8.6%) | 78 (55.7%) | NA | NA | NA |
43 | Tsibouris P et al. | 61 | 16 (26.2%) | 11 (18.0%) | 11 (18.0%) | 4 (6.6%) | 2 (3.3%) |
44 | Vena A et al. | 275 | 120 (43.6%) | 14 (5.1%) | 14(5.1%) | 11(4.0%) | NA |
45 | Villanego F et al. | 1011 | 220 (21.8%) | 323 (31.9%) | NA | NA | NA |
46 | Vrillon A et al. | 52 | 17 (32.7%) | 17 (32.7%) | NA | NA | NA |
47 | Wan, Y et al. | 230 | 6 (2.6%) | 49 (21.3%) | 49 (21.3%) | NA | NA |
48 | Wang Z et al. | 59 | 41 (69.5%) | 22 (37.3%) | 22 (37.3%) | 4 (6.8%) | NA |
49 | Yang X et al. | 52 | 32 (61.5%) | 2 (3.8%) | NA | 2 (3.8%) | NA |
50 | Zhang J et al. | 663 | 25 (3.8%) | 61 (9.2%) | 61 (9.2%) | 31 (4.7%) | 5 (0.8%) |
51 | Zhang L et al. | 409 | 102 (24.9%) | 91 (22.2%) | 91 (22.2%) | 50 (12.2%) | 28 (6.8%) |
52 | Zhou F et al. | 191 | 54 (28.3%) | 9 (4.7%) | 9 (4.7%) | 7 (3.7%) | NA |
53 | Zhou Z et al. | 254 | 16 (6.3%) | 66 (26.0%) | NA | NA | NA |
Cumulative incidence | Â | Â | 25% | 16% | 7.5% | 3.6% | |